{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T10:24:25Z","timestamp":1787394265675,"version":"build-2736575974"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010400","name":"Children's Mercy Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ymthe.2026.08.007","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:38:11Z","timestamp":1786405091000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipid nanoparticle-based multi-scale systemic immune programming for cancer therapy"],"prefix":"10.1016","author":[{"given":"Xinwen","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiling","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5006-9143","authenticated-orcid":false,"given":"Bowen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7672-9170","authenticated-orcid":false,"given":"Yue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.08.007_bib1","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ymthe.2026.08.007_bib2","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune Checkpoint Inhibitors in Cancer Therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ymthe.2026.08.007_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12964-025-02632-y","article-title":"Immune cell-based therapies for solid tumors, current challenges and therapeutic advances","volume":"24","author":"Torabi","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ymthe.2026.08.007_bib4","article-title":"Targeting tumor microenvironmental barriers to enhance immunogenic cell death in solid tumors","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.08.007_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T Cell Toxicity: Current Management and Future Directions","volume":"3","author":"Y\u00e1\u00f1ez","year":"2019","journal-title":"Hemasphere"},{"key":"10.1016\/j.ymthe.2026.08.007_bib6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2026.08.007_bib7","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41409-020-0956-8","article-title":"Value and affordability of CAR T-cell therapy in the United States","volume":"55","author":"Fiorenza","year":"2020","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.ymthe.2026.08.007_bib8","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: The evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.08.007_bib9","article-title":"Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.08.007_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1039\/D5NH00432B","article-title":"Lipid nanoparticles for engineering next generation CAR T cell immunotherapy","volume":"11","author":"Ang","year":"2026","journal-title":"Nanoscale Horiz."},{"key":"10.1016\/j.ymthe.2026.08.007_bib11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41571-023-00734-5","article-title":"Cancer-associated cachexia\u2014understanding the tumour macroenvironment and microenvironment to improve management","volume":"20","author":"Argil\u00e9s","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.08.007_bib12","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.1016\/j.cell.2025.07.016","article-title":"Vagal blockade of the brain-liver axis deters cancer-associated cachexia","volume":"188","author":"Garrett","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.08.007_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1680071","article-title":"Incorporating mRNA therapeutics into biological treatments of hematologic malignancies","volume":"16","author":"Hunia","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.08.007_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.7774\/cevr.2025.14.e40","article-title":"Advancements and challenges in next-generation mRNA vaccine manufacturing systems","volume":"14","author":"Seo","year":"2025","journal-title":"Clin. Exp. Vaccin. Res."},{"key":"10.1016\/j.ymthe.2026.08.007_bib15","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s41587-019-0247-3","article-title":"Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation","volume":"37","author":"Miao","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.08.007_bib16","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/s41551-024-01256-w","article-title":"Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d","volume":"8","author":"Chaudhary","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2026.08.007_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1670350","article-title":"The mRNA component of LNP-mRNA vaccines triggers IFNAR-dependent immune activation which attenuates the adaptive immune response","volume":"16","author":"Bar-On","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.08.007_bib18","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.mattod.2022.11.007","article-title":"Self-Therapeutic Nanomaterials: Applications in Biology and Medicine","volume":"62","author":"Seaberg","year":"2023","journal-title":"Mater. Today"},{"key":"10.1016\/j.ymthe.2026.08.007_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1336906","article-title":"The mRNA-LNP vaccines - the good, the bad and the ugly?","volume":"15","author":"Igy\u00e1rt\u00f3","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.08.007_bib20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12951-025-03800-5","article-title":"mRNA vaccines: immunogenicity and quality characteristics","volume":"24","author":"Quan","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ymthe.2026.08.007_bib21","doi-asserted-by":"crossref","first-page":"8699","DOI":"10.1038\/s41467-025-63726-2","article-title":"Protein corona formed on lipid nanoparticles compromises delivery efficiency of mRNA cargo","volume":"16","author":"Voke","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.08.007_bib22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41541-025-01124-x","article-title":"Ionizable lipid nanoparticles of mRNA vaccines elicit NF-\u03baB and IRF responses through toll-like receptor 4","volume":"10","author":"Zelkoski","year":"2025","journal-title":"npj Vaccin."},{"key":"10.1016\/j.ymthe.2026.08.007_bib23","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1021\/acs.accounts.5c00522","article-title":"Ionizable Lipid Nanoparticles for mRNA Delivery: Internal Self-Assembled Inverse Mesophase Structure and Endosomal Escape","volume":"58","author":"Yu","year":"2025","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ymthe.2026.08.007_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113945","article-title":"Impact of ionizable lipid type on the pharmacokinetics and biodistribution of mRNA-lipid nanoparticles after intravenous and subcutaneous injection","volume":"384","author":"Ren","year":"2025","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2026.08.007_bib25","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3390\/jpm14090993","article-title":"Effectiveness and Safety of mRNA Vaccines in the Therapy of Glioblastoma","volume":"14","author":"Strika","year":"2024","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.ymthe.2026.08.007_bib26","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood.2024026781","article-title":"Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation","volume":"145","author":"Li","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.08.007_bib27","doi-asserted-by":"crossref","first-page":"160.18","DOI":"10.4049\/jimmunol.210.Supp.160.18","article-title":"The BNT162b2 vaccine\u2019s empty lipid nanoparticle is able to induce an NF-\u03baB response","volume":"210","author":"Zelkoski","year":"2023","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.08.007_bib28","doi-asserted-by":"crossref","DOI":"10.34133\/bmr.0178","article-title":"Current Trends in Messenger RNA Technology for Cancer Therapeutics","volume":"29","author":"Afzal","year":"2025","journal-title":"Biomater. Res."},{"key":"10.1016\/j.ymthe.2026.08.007_bib29","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.08.007_bib30","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00018-010-0605-2","article-title":"The STING pathway and regulation of innate immune signaling in response to DNA pathogens","volume":"68","author":"Ishikawa","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ymthe.2026.08.007_bib31","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.08.007_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Karik\u00f3","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.08.007_bib33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jconrel.2024.03.018","article-title":"Plasmid DNA ionisable lipid nanoparticles as non-inert carriers and potent immune activators for cancer immunotherapy","volume":"369","author":"Qin","year":"2024","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2026.08.007_bib34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41587-025-02556-5","article-title":"Safer non-viral DNA delivery using lipid nanoparticles loaded with endogenous anti-inflammatory lipids","volume":"44","author":"Patel","year":"2026","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.08.007_bib35","doi-asserted-by":"crossref","first-page":"7226","DOI":"10.1038\/s41467-024-51411-9","article-title":"Innate immune responses against mRNA vaccine promote cellular immunity through IFN-\u03b2 at the injection site","volume":"15","author":"Kim","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.08.007_bib36","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41564-021-00884-1","article-title":"ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity","volume":"6","author":"Liu","year":"2021","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ymthe.2026.08.007_bib37","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20241148","article-title":"Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection","volume":"222","author":"Broomfield","year":"2025","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.08.007_bib38","doi-asserted-by":"crossref","first-page":"eaaz6893","DOI":"10.1126\/sciadv.aaz6893","article-title":"Impact of mRNA chemistry and manufacturing process on innate immune activation","volume":"6","author":"Nelson","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2026.08.007_bib39","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1021\/acscentsci.1c00197","article-title":"Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines","volume":"7","author":"Nance","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ymthe.2026.08.007_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1291045","article-title":"Formation of dsRNA by-products during in vitro transcription can be reduced by using low steady-state levels of UTP","volume":"10","author":"Ziegenhals","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ymthe.2026.08.007_bib41","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.08.007_bib42","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.cell.2024.03.018","article-title":"Self-amplifying RNA COVID-19 vaccine","volume":"187","author":"Wayne","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.08.007_bib43","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ymthe.2025.10.038","article-title":"CircRNA: unlocking new frontiers in therapeutic and vaccine development","volume":"34","author":"Bahrulolum","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.08.007_bib44","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf089","article-title":"Characterization of group I introns in generating circular RNAs as vaccines","volume":"53","author":"Liao","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.08.007_bib45","article-title":"Circular RNAs: Novel Players in Cancer Mechanisms and Therapeutic Strategies","volume":"25","author":"Kim","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.08.007_bib46","article-title":"Harnessing the Loop: The Perspective of Circular RNA in Modern Therapeutics","volume":"13","author":"Zhao","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2026.08.007_bib47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.ymthe.2026.08.007_bib48","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1038\/s41467-024-50950-5","article-title":"Reprogramming the tumor immune microenvironment using engineered dual-drug loaded Salmonella","volume":"15","author":"Nguyen","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.08.007_bib49","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cac2.12539","article-title":"Immunologic tumor microenvironment modulators for turning cold tumors hot","volume":"44","author":"Khosravi","year":"2024","journal-title":"Cancer Commun."},{"key":"10.1016\/j.ymthe.2026.08.007_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202470228","article-title":"Tumor-Tailored Ionizable Lipid Nanoparticles Facilitate IL-12 Circular RNA Delivery for Enhanced Lung Cancer Immunotherapy","volume":"36","author":"Xu","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ymthe.2026.08.007_bib51","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.biomaterials.2016.07.003","article-title":"Efficient production and enhanced tumor delivery of engineered extracellular vesicles","volume":"105","author":"Watson","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2026.08.007_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax0876","article-title":"Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies","volume":"12","author":"Gurbatri","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.08.007_bib53","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.3390\/ijms24044002","article-title":"Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment","volume":"24","author":"Habanjar","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.08.007_bib54","article-title":"Local administration of mRNA encoding cytokine cocktail confers potent anti-tumor immunity","volume":"15","author":"Li","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.08.007_bib55","doi-asserted-by":"crossref","first-page":"LB198","DOI":"10.1158\/1538-7445.AM2023-LB198","article-title":"Abstract LB198: A first-in-human, open-label, multicenter study of intratumoral SAR441000 (mixture of cytokine encoding mRNAs), as monotherapy and in combination with cemiplimab in patients with advanced solid tumors","volume":"83","author":"Bechter","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2026.08.007_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115190","article-title":"mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond","volume":"206","author":"Estap\u00e9 Senti","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2026.08.007_bib57","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1158\/1078-0432.CCR-20-0472","article-title":"Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment","volume":"26","author":"Hewitt","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.08.007_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat9143","article-title":"Durable anticancer immunity from intratumoral administration of IL-23, IL-36\u03b3, and OX40L mRNAs","volume":"11","author":"Hewitt","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.08.007_bib59","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1038\/s41467-019-11911-5","article-title":"Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.08.007_bib60","doi-asserted-by":"crossref","DOI":"10.1063\/5.0247029","article-title":"Lipid nanoparticle-assisted mRNA therapy for cancer treatment","volume":"12","author":"Kim","year":"2025","journal-title":"Appl. Phys. Rev."},{"key":"10.1016\/j.ymthe.2026.08.007_bib61","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.08.007_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011642","article-title":"Preclinical and clinical evaluation of intratumoral injection of an IL-12 expressing SKV-012 oncolytic virus for advanced solid tumors","volume":"13","author":"Jiang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.08.007_bib63","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41551-020-0549-2","article-title":"Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours","volume":"4","author":"Mansurov","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2026.08.007_bib64","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1021\/acs.nanolett.4c05186","article-title":"Peptide-Functionalized Lipid Nanoparticles for Targeted Systemic mRNA Delivery to the Brain","volume":"25","author":"Han","year":"2025","journal-title":"Nano Lett."},{"key":"10.1016\/j.ymthe.2026.08.007_bib65","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1038\/s41565-025-02045-5","article-title":"A modular mRNA platform for programmable induction of tumour-specific immunogenic cell death","volume":"20","author":"Dong","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ymthe.2026.08.007_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121339","article-title":"In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift","volume":"281","author":"Kheirolomoom","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2026.08.007_bib67","article-title":"Therapeutic Potential of Lipid Nanoparticle-Encapsulated CD19-Targeting mRNAs in Lupus and Rheumatoid Arthritis","volume":"12","author":"Guo","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ymthe.2026.08.007_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/science.adu9394","article-title":"Single intramuscular injection of self-amplifying RNA of Nppa to treat myocardial infarction","volume":"391","author":"Zhang","year":"2026","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.08.007_bib69","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.08.007_bib70","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1016\/j.ymthe.2022.07.007","article-title":"mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells","volume":"30","author":"Bevers","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.08.007_bib71","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Lett."},{"key":"10.1016\/j.ymthe.2026.08.007_bib72","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrm.2017.91","article-title":"Codon optimality, bias and usage in translation and mRNA decay","volume":"19","author":"Hanson","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ymthe.2026.08.007_bib73","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.molcel.2019.02.015","article-title":"RNA Circularization Diminishes Immunogenicity and Can Extend Translation Duration In Vivo","volume":"74","author":"Wesselhoeft","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ymthe.2026.08.007_bib74","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.08.007_bib75","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1182\/blood-2024-203585","article-title":"Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Disease","volume":"144","author":"Miljkovic","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.08.007_bib76","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.08.007_bib77","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.08.007_bib78","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.08.007_bib79","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.08.007_bib80","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.08.007_bib81","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12943-025-02386-8","article-title":"Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives","volume":"24","author":"Azeez","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2026.08.007_bib82","doi-asserted-by":"crossref","first-page":"17","DOI":"10.32607\/actanaturae.27707","article-title":"mRNA-Based Personalized Cancer Vaccines: Opportunities, Challenges and Outcomes","volume":"17","author":"Ibragimova","year":"2025","journal-title":"Acta Naturae"},{"key":"10.1016\/j.ymthe.2026.08.007_bib83","article-title":"Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy","volume":"14","author":"Imani","year":"2024","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.ymthe.2026.08.007_bib84","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ymthe.2026.08.007_bib85","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1038\/s41467-024-50619-z","article-title":"AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery","volume":"15","author":"Xu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.08.007_bib86","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.cell.2026.01.012","article-title":"LUMI-lab: A foundation model-driven autonomous platform enabling discovery of ionizable lipid designs for mRNA delivery","volume":"189","author":"Xu","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.08.007_bib87","article-title":"Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response","volume":"119","author":"Chen","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.08.007_bib88","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/s41563-025-02284-w","article-title":"Albumin-recruiting lipid nanoparticle potentiates the safety and efficacy of mRNA vaccines by avoiding liver accumulation","volume":"24","author":"Feng","year":"2025","journal-title":"Nat. Mater."},{"key":"10.1016\/j.ymthe.2026.08.007_bib89","doi-asserted-by":"crossref","first-page":"LBA9503","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9503","article-title":"Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201\/KEYNOTE-942 trial","volume":"41","author":"Khattak","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.08.007_bib90","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.08.007_bib91","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3390\/cancers17111882","article-title":"Current Progress and Future Perspectives of RNA-Based Cancer Vaccines: A 2025 Update","volume":"17","author":"Magoola","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.ymthe.2026.08.007_bib92","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.08.007_bib93","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","article-title":"Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial","volume":"31","author":"Lopez","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.08.007_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102780","article-title":"mRNA-LNP vaccination orchestrates systemic immunity to control human papillomavirus-positive head and neck squamous cell carcinoma","volume":"36","author":"Qiu","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.08.007_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102823","article-title":"A symphony of immunity: How HPV mRNA-LNP vaccination orchestrates systemic anti-tumor responses","volume":"37","author":"Elia","year":"2026","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.08.007_bib96","unstructured":"Erez, A., Goldman, O., Hajaj, E., and Schroeder, A. (2025). Reexpression of Hnf4a to Alleviate Cancer-Associated Cachexia. Google Patents."},{"key":"10.1016\/j.ymthe.2026.08.007_bib97","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1039\/D5PM00079C","article-title":"A new strategy for the extrahepatic delivery of lipid-based nanomedicines: a protein corona-mediated selective targeting system based on an ionizable cationic lipid library","volume":"2","author":"Younis","year":"2025","journal-title":"RSC Pharm."},{"key":"10.1016\/j.ymthe.2026.08.007_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21124365","article-title":"Biological Functions and Therapeutic Potential of Lipocalin 2 in Cancer","volume":"21","author":"Santiago-S\u00e1nchez","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.08.007_bib99","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.cell.2026.01.024","article-title":"Liver exerkine reverses aging- and Alzheimer\u2019s-related memory loss via vasculature","volume":"189","author":"Bieri","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.08.007_bib100","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/s41556-024-01543-3","article-title":"Hepatocellular senescence induces multi-organ senescence and dysfunction via TGF\u03b2","volume":"26","author":"Kiourtis","year":"2024","journal-title":"Nat. Cell Biol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162600688X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162600688X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:34:54Z","timestamp":1787391294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162600688X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":100,"alternative-id":["S152500162600688X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.08.007","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid nanoparticle-based multi-scale systemic immune programming for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}